Assignee
ALFASIGMA SPA
IT·20 granted patents·23 pending applications·7 citations·filing 2013–2025
Top patents by PatentIndex Score
43 records- 0196US12234235B2Salts and pharmaceutical compositions thereof for the treatment of inflammatory disordersALFASIGMA SPA·Filed 2023·Granted Feb 25, 2025·2 cites·4 claims
- 0295US12042498B2Compound useful for the treatment of degenerative and inflammatory diseasesALFASIGMA SPA·Filed 2021·Granted Jul 23, 2024·5 cites·10 claims
- 0390US12558360B2Compound useful for the treatment of degenerative and inflammatory diseasesALFASIGMA SPA·Filed 2024·Granted Feb 24, 2026·0 cites·12 claims
- 0482US12502394B2Pharmaceutical compositions comprising a JAK inhibitorALFASIGMA SPA·Filed 2024·Granted Dec 23, 2025·0 cites·14 claims
- 0580US2022119403A1Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparationsALFASIGMA SPA·Filed 2021·Application pending·0 cites
- 0680US2022127283A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2022·Application pending·0 cites
- 0776US2025289816A1Salts and pharmacutical compositions thereof for the treatment of inflammatory disordersALFASIGMA SPA·Filed 2025·Application pending·0 cites
- 0873US10703763B2Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparationsALFASIGMA SPA·Filed 2019·Granted Jul 7, 2020·0 cites·9 claims
- 0973US2020339599A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 1073US2019263829A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2019·Application pending·0 cites
- 1173US2020277301A1Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparationsALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 1273US2020339600A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 1371US2019263830A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2019·Application pending·0 cites
- 1470US2024050497A1Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acidALFASIGMA SPA·Filed 2023·Application pending·0 cites
- 1570US2019135831A1Polymorphic forms alpha, beta and gamma of rifaximinALFASIGMA SPA·Filed 2018·Application pending·0 cites
- 1668US2019135830A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2018·Application pending·0 cites
- 1767US12201729B2Process for mesalazine solid formulationsALFASIGMA SPA·Filed 2022·Granted Jan 21, 2025·0 cites·20 claims
- 1866US2018291032A1Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparationsALFASIGMA SPA·Filed 2017·Application pending·0 cites
- 1965US10793925B2Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereofALFASIGMA SPA·Filed 2019·Granted Oct 6, 2020·0 cites·11 claims
- 2065US2021244714A1Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal diseaseALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 2164US11839634B2Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acidALFASIGMA SPA·Filed 2014·Granted Dec 12, 2023·0 cites·10 claims
- 2261US2025360177A1Fermentation product for the treatment of inflammatory diseasesALFASIGMA SPA·Filed 2023·Application pending·0 cites
- 2361US2020000726A1Gastroresistant pharmaceutical formulations containing rifaximinALFASIGMA SPA·Filed 2019·Application pending·0 cites
- 2460US11751597B2Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systemsALFASIGMA SPA·Filed 2020·Granted Sep 12, 2023·0 cites·13 claims
- 2559US10285944B2Gastroresistant pharmaceutical formulations containing rifaximinALFASIGMA SPA·Filed 2013·Granted May 14, 2019·0 cites·44 claims
- 2658US2025325606A1Lacticaseibacillus paracasei dg(r) cncm i-1572 dsm 34154 for use in a method of treating dysbiosis in patients with ibsALFASIGMA SPA·Filed 2023·Application pending·0 cites
- 2758US2024350567A1Use of lactobacillus paracasei bacterial strains in the treatment of newbornsALFASIGMA SPA·Filed 2022·Application pending·0 cites
- 2857US11433043B2Compounds useful for increasing neurogenesis in neural tissueALFASIGMA SPA·Filed 2020·Granted Sep 6, 2022·0 cites·4 claims
- 2957US10280177B2Use of polyols to obtain stable polymorphous forms of rifaximinALFASIGMA SPA·Filed 2016·Granted May 7, 2019·0 cites·10 claims
- 3057US2022119410A1Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximinALFASIGMA SPA·Filed 2021·Application pending·0 cites
- 3153US12472214B2Bacterial strains, the compositions thereof and use thereof in a method for the treatment of vitamin D deficiency, and disorders associated therewithALFASIGMA SPA·Filed 2021·Granted Nov 18, 2025·0 cites·6 claims
- 3253US2023181475A1Composition comprising methylfolateALFASIGMA SPA·Filed 2021·Application pending·0 cites
- 3352US12447183B2Bacterial strains, their compositions and their use for the treatment of gastrointestinal disordersALFASIGMA SPA·Filed 2020·Granted Oct 21, 2025·0 cites·5 claims
- 3452US11752179B2Medical use of probioticsALFASIGMA SPA·Filed 2017·Granted Sep 12, 2023·0 cites·16 claims
- 3550US10428086B2Solvated crystal form of rifaximin, production, compositions and uses thereofALFASIGMA SPA·Filed 2018·Granted Oct 1, 2019·0 cites·3 claims
- 3648US11241452B2Oral compositions for the treatment of gastroesophageal refluxALFASIGMA SPA·Filed 2018·Granted Feb 8, 2022·0 cites·13 claims
- 3745US11896631B2Probiotics for use in the treatment of diverticulosis and diverticular diseaseALFASIGMA SPA·Filed 2017·Granted Feb 13, 2024·0 cites·20 claims
- 3843US2022241193A1Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredientsALFASIGMA SPA·Filed 2020·Application pending·0 cites
- 3943US2021128740A1HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPYALFASIGMA SPA·Filed 2018·Application pending·0 cites
- 4042US2019388411A1Nsaid administration and related compositions, methods and systemsALFASIGMA SPA·Filed 2019·Application pending·0 cites
- 4141US10300035B2Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administrationALFASIGMA SPA·Filed 2015·Granted May 28, 2019·0 cites·16 claims
- 4237US2018187274A1Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereofALFASIGMA SPA·Filed 2016·Application pending·0 cites
- 4329US12329758B2Methods for the treatment of psoriatic arthritisALFASIGMA SPA·Filed 2019·Granted Jun 17, 2025·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when ALFASIGMA SPA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →